Emergent Biosolutions (NYSE:EBS) had its "hold (c-)" rating reaffirmed by analysts at
Weiss Ratings.
Emergent Biosolutions (NYSE:EBS) was upgraded by analysts at
Wall Street
Emergent Biosolutions (NYSE:EBS) had its "hold (c-)" rating reaffirmed by analysts at
Weiss Ratings.
Emergent BioSolutions Marks 10-Year Anniversary of the U.S. FDA Approval of NARCAN® Nasal Spray and Reinforces its Commitment to Increasing Naloxone Access
Emergent BioSolutions Announces Retirement of Dr. Louis W. Sullivan from Board of Directors [Yahoo! Finance]